Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Mycobacterium Fortuitum

  • Author: Joseph M Fritz, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD  more...
 
Updated: Oct 05, 2015
 

Background

Mycobacterium fortuitum is a nontuberculous mycobacterium (NTM), a grouping that encompasses all mycobacteria outside of the Mycobacterium tuberculosis complex. M fortuitum is classified in the Runyon group IV, rapidly growing mycobacteria.[1] It has been found in natural and processed water sources, as well as in sewage and dirt. Distribution is probably worldwide. 

Next

Pathophysiology

M fortuitum infection can cause various clinical syndromes. It is an uncommon cause of NTM lung disease. Local cutaneous disease, osteomyelitis, joint infections, and ocular disease (eg, keratitis, corneal ulcers) may occur after trauma. M fortuitum infection is a rare cause of isolated lymphadenitis. Disseminated disease, usually with disseminated skin lesions and soft tissue lesions, occurs almost exclusively in the setting of severe immunosuppression, especially AIDS. Endocarditis has been documented.

Surgical-site infections due to M fortuitum infection are well-documented, especially in association with cardiothoracic surgery. The source is frequently contamination of the wound, directly or indirectly, with colonized tap water. Other nosocomial infections with this organism include infections of implanted devices (eg, catheters) and injection-site abscesses. Pseudo-outbreaks have been associated with contaminated endoscopes. Recent outbreaks have also been described in immunocompetent hosts after use of contaminated whirlpool footbaths in nail salons.[2]

Previous
Next

Epidemiology

Frequency

United States

NTM infections are not required to be reported; therefore, exact estimates of disease prevalence and incidence are impossible to determine. The most recent estimates come from voluntary reports tracked by the Centers for Disease Control and Prevention (CDC). From 1993-1996, 4.65-5.99 cases per million persons were reported to the CDC.[3] Sputum was the most frequently reported site, but this may represent a bias in the sites most likely to be cultured for mycobacteria.

Most cases are reported from the southeast United States, including Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia, and the south-central United States, including Arkansas, Kansas, Louisiana, Missouri, Oklahoma, and Texas. Because all cases were likely not reported and some positive culture results may not represent disease, which is perhaps especially true of positive sputum culture results, these numbers may significantly overestimate or underestimate true disease incidence. However, they suggest the general order of magnitude of the situation. An increased appreciation of these organisms as true pathogens may be the reason NTM infection rates are perceived to be increasing, even excluding Mycobacterium avium complex (MAC) infections in persons with AIDS.

International

The World Health Organization does not track NTM infections. Incidence and prevalence undoubtedly vary greatly by locale.

Mortality/Morbidity

Mortality due to localized M fortuitum infection is rare. Death may result from extensive pulmonary or disseminated disease in patients who are immunocompromised.

Morbidity depends largely on the site of the infection. Localized skin lesions may eventually heal without therapy or surgical intervention. At other sites, chronic infection is the rule.

Race

No clear racial predilection exists.

Sex

No sexual predominance is known; however, from 1993-1996, more cases reported to the CDC were involved men than did women.[3] Whether this represents a true sex-based preference or reflects a bias in testing and reporting is unclear.

Age

In general, no known age predominance exists. Lung disease in a younger patient (< 50 y) strongly suggests a primary underlying lung disorder. Isolated lymphadenitis primarily occurs in children.

Previous
 
 
Contributor Information and Disclosures
Author

Joseph M Fritz, MD Fellow, Division of Infectious Diseases, Washington University School of Medicine, Barnes Jewish Hospital

Joseph M Fritz, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron Glatt, MD Chief Administrative Officer, Executive Vice President, Mercy Medical Center, Catholic Health Services of Long Island

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American Association for Physician Leadership, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Chief Editor

Pranatharthi Haran Chandrasekar, MBBS, MD Professor, Chief of Infectious Disease, Program Director of Infectious Disease Fellowship, Department of Internal Medicine, Wayne State University School of Medicine

Pranatharthi Haran Chandrasekar, MBBS, MD is a member of the following medical societies: American College of Physicians, American Society for Microbiology, International Immunocompromised Host Society, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Keith F Woeltje, MD, PhD Professor, Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine

Keith F Woeltje, MD, PhD is a member of the following medical societies: American College of Physicians, American Medical Informatics Association, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

References
  1. Ho YS, Adroub SA, Aleisa F, Mahmood H, Othoum G, Rashid F, et al. Complete Genome Sequence of Mycobacterium fortuitum subsp. fortuitum Type Strain DSM46621. J Bacteriol. 2012 Nov. 194(22):6337-8. [Medline]. [Full Text].

  2. Winthrop KL, Abrams M, Yakrus M, Schwartz I, Ely J, Gillies D, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med. 2002 May 2. 346(18):1366-71. [Medline].

  3. CDC. Nontuberculous mycobacteria reported to the Public Health Laboratory Information System by State Public Health Laboratories United States, 1993-1996. [Full Text].

  4. Jiang SH, Roberts DM, Dawson AH, Jardine M. Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. BMC Nephrol. 2012 Jun 8. 13:35. [Medline]. [Full Text].

  5. Sparks R, Khatami A. Mycobacterium Fortuitum Complex Skin Infection in a Healthy Adolescent. Infect Disord Drug Targets. 2014 Jul 13. [Medline].

  6. Philips RC, Hunter-Ellul LA, Martin JE, Wilkerson MG. Mycobacterium fortuitum infection arising in a new tattoo. Dermatol Online J. 2014 Jun 15. 20(6):[Medline].

  7. ATS. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug. 156(2 Pt 2):S1-25. [Medline].

  8. Cruz AT, Antekeier SB. Chronic multifocal Mycobacterium fortuitum osteomyelitis following penetrating plantar trauma. Am J Orthop (Belle Mead NJ). 2012 Aug. 41(8):E109-11. [Medline].

  9. Wallace RJ, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985 Sep. 152(3):500-14. [Medline].

  10. Heifets LB. Antimycobacterial drugs. Semin Respir Infect. 1994 Jun. 9(2):84-103. [Medline].

  11. Brown-Elliott BA, Wallace RJ, Crist CJ. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002 Oct. 46(10):3283-5. [Medline].

  12. Wallace RJ, Brown-Elliott BA, Crist CJ. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002 Oct. 46(10):3164-7. [Medline].

  13. Sethi S, Arora S, Gupta V, Kumar S. Cutaneous Mycobacterium fortuitum Infection: Successfully Treated with Amikacin and Ofloxacin Combination. Indian J Dermatol. 2014 Jul. 59(4):383-4. [Medline]. [Full Text].

  14. ATS/IDSA: Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. February 2007. 175:367-416. [Medline].

  15. Bhambri S, Bhambri A, Del Rosso JQ. Atypical mycobacterial cutaneous infections. Dermatol Clin. 2009 Jan. 27(1):63-73. [Medline].

  16. Esteban J, Ortiz-Pérez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother. 2009 Dec. 10(17):2787-99. [Medline].

  17. Griffith DE, Wallace RJ. New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect. 1996 Dec. 11(4):301-10. [Medline].

  18. Kyle SD, Porter WM. Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid. Br J Dermatol. 2004 Nov. 151(5):1101. [Medline].

  19. Porat MD, Austin MS. Bilateral knee periprosthetic infection with Mycobacterium fortuitum. J Arthroplasty. 2008 Aug. 23(5):787-9. [Medline].

  20. Wagner D, Young LS. Nontuberculous mycobacterial infections: a clinical review. Infection. 2004 Oct. 32(5):257-70. [Medline].

  21. Wallace RJ, Brown-Elliott BA, Ward SC. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001 Mar. 45(3):764-7. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.